ERBB2 and breast cancer: In patients with locally recurrent unresectable or metastatic HR+/HER2- BC, next-generation sequencing-based analyses of tumor tissue samples or plasma ctDNA should be to detect mutations in PIK3CA in order to determine whether patients are eligible for treatment with the phosphatidylinositol 3-kinase inhibitor alpelisib plus fulvestrant (135).